Effect of Reveromycin A on experimental tooth movement in OPG-/- mice.
In osteoprotegerin-deficient (OPG-/-) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified as the unique agent acting on osteoclast activation. This study aimed to analyze the effect of RM-A on the orthodontic treatment of OPG-/- mice (a model of osteoporosis patients with high levels of bone turnover). We examined alveolar bone remodeling in OPG-/- and wild-type (WT) mice during continuous tooth movement. The orthodontic force was induced by means of a Ni-Ti closed-coil spring to move the maxillary first molar for 14 days. RM-A sodium salt (1 mg/kg) was administered intraperitoneally twice daily. In OPG-/- mice, the tooth movement distance was longer, alveolar bone resorption was enhanced, the osteoclast count was greater, and serum alkaline phosphatase and tartrate-resistant acid phosphatase levels were higher relative to those in WT mice. However, the administration of RM-A in OPG-/- mice reduced these parameters. We conclude that RM-A normalizes bone metabolism and loss of alveolar bone during continuous tooth movement in OPG-/- mice.
Department of Orthodontics, School of Dentistry, Aichi-Gakuin University, Chikusa-ku, Nagoya, Japan. miumiu@dpc.agu.ac.jp
M
M
Tanaka
K
K
Miyazawa
M
M
Tabuchi
T
T
Yabumoto
M
M
Kadota
M
M
Yoshizako
C
C
Yamane
M
M
Kawatani
H
H
Osada
H
H
Maeda
S
S
Goto
D000135:Acid Phosphatase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000539:Alveolar Process / Q000187:drug effects* / Q000473:pathology; D000818:Animals; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000473:pathology / Q000503:physiopathology; D002452:Cell Count; D003722:Dental Alloys / Q000737:chemistry; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008437:Maxilla / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009154:Mutation / Q000235:genetics; D009532:Nickel / Q000737:chemistry; D009969:Orthodontic Wires; D010001:Osteitis Deformans / Q000235:genetics / Q000503:physiopathology; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010024:Osteoporosis / Q000235:genetics / Q000503:physiopathology; D053244:Osteoprotegerin / Q000235:genetics; D011714:Pyrans / Q000008:administration & dosage / Q000494:pharmacology*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D000071681:Tartrate-Resistant Acid Phosphatase; D014025:Titanium / Q000737:chemistry; D014087:Tooth Movement Techniques; D055114:X-Ray Microtomography
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D003722:Dental Alloys; D007527:Isoenzymes; D053244:Osteoprotegerin; D011714:Pyrans; D013141:Spiro Compounds; C506031:Tnfrsf11b protein, mouse; C040654:titanium nickelide; C068098:reveromycin A; D009532:Nickel; D014025:Titanium; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase